Impact of minimal inhibitory concentration breakpoints on local cumulative bacterial susceptibility data and antibiotic consumption

Table 4 Species/drug combinations with changes ≥ 10% in the category susceptible after implementation of EUCAST MIC breakpoints

	Assignment of clinical isolates to AST categories (%)
	Q3 2011-Q2 2012 (DIN)			Q3 2012-Q2 2013^*(EUCAST)
*Species*^#/drug	S	I	R	S	I	R
E. cloacae	n = 77				n = 41
ciprofloxacin	97	0	3	85^*	9	6
S. marcescens	n = 116				n = 93
ciprofloxacin	99	0	1	88^*	9	3
M. morganii	n = 107			n = 92
ciprofloxacin	97	0	3	82^*	10	8
C. freundii	n = 93			n = 89
pip/taz	77	4	19	87^*	4	9
P. aeruginosa	n = 462			n = 444
piperacillin	41	53	7	81^*	3	16
gentamicin	55	36	9	92^*	0	8

^*Asterisks indicate a significant (p < 0.05) of the number of susceptible isolates according to EUCAST MIC breakpoints compared to DIN.
^#No variation ≥ 10% in the category susceptible was found for E. coli, K. pneumoniae, P. mirabilis, S. maltophilia, A. baumannii, S. aureus, coagulase negative staphylococci, E. feacalis, and E. faecium.

ISSN: 1756-0500